Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.40 on Wednesday. The firm has a market cap of $2.24 million, a P/E ratio of -0.05 and a beta of 0.50. The stock’s 50-day moving average is $0.93 and its two-hundred day moving average is $1.26. Oragenics has a fifty-two week low of $0.40 and a fifty-two week high of $7.74.

Oragenics (NYSE:OGEN) last posted its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.